On the one hand, anti-cancer compounds containing a BPA conjugate with an epidermal growth factor (EGF) ligand or anti-EGFR antibody (mAbs, cetuximab (C225)) or anti-EGFRvIII mutation antibody (L8A4), and specifically recognize wild-type EGFR and EGFRvIII. The gene discussed is EGF; the disease is cancer.